Tazemetostat Pill

DRUG3 trials

Sponsors

University of British Columbia, Weill Medical College of Cornell University

Conditions

B-Cell LymphomaDiffuse Large B Cell LymphomaFollicular LymphomaMantle Cell LymphomaProstate Cancer

Phase 1

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Active, not recruitingNCT05934838

Weill Medical College of Cornell UniversityB-Cell Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma +1

Start: 2023-10-04End: 2031-09-01Target: 15Updated: 2026-06-17

Phase 2

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

RecruitingNCT04812366

University of British ColumbiaProstate Cancer

Start: 2021-09-21End: 2027-06-01Target: 315Updated: 2026-08-14

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Active, not recruitingNCT05994235

Weill Medical College of Cornell UniversityFollicular Lymphoma

Start: 2023-11-01End: 2033-10-01Updated: 2026-04-02

Related Papers

3D Structural Revelations of Neoadjuvant Hormonal Therapy Treatment in High Risk Localized Prostate Cancer by Light-Sheet Imaging.

Journal of Clinical Oncology2026-05-28

Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CAR T-cell therapy.

Journal of Clinical Oncology2026-05-27

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial.

2025-03-101 citations

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

2025-03-074 citations

Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).

Journal of Clinical Oncology2025-02-101 citations

EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.

2024-12-0523 citations

Abstract PR01: EZH2 inhibitors improve CAR-T therapy by enhancing lymphoma B cell immunogenicity and CAR-T cell functions

Blood Cancer Discovery2024-06-19

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Blood2023-11-026 citations